Table Of Content

Author Index Articles appearing on AJKD Electronic Pages are referred to by journal number, a colon, the letter E, and a number. Page references to Supplement 1 (January 2007) are preceded by S1:. Aasar@d, K., 396 Beyer, U., 989 Cheung, A.K., 791 Abas, H., 574 Bhat, P., 641 Cheung, A.L., 342, 343 Abbott, K.C., 345 Bienaimé, F., 821 Chiang, S.-S., 124 Adams, A.L., 681 Billemont, B., 203 Chonchol, M., 219, 239 Adelson, A.B., 450 Bjorneklett, R., 396 Chueh, S.-C., 743 Agarwal, R., 1009 Block, C., 151, 1053 Chung, S.-D., 743 Aggarwal, N., 826 Bodenheimer, H.C. Jr., 645 Ciechanowski, K., 989 Ahmed, M.S., 1028 Bohen, E.M., 345 Clerbaux, G., 821 Akai, Y., 47 Bora, S., 143 Clyne, S., 946 Akizawa, T., 602 Borrelli, S., 908 Coca, S.G., 712 Al-AlSheikh, K., 1:xxxiii Bostad, L., 396 Cohen, A.J., 585 Al-Aly, Z., 59 Bouchard, J., 566 Cohen, J.T., 362 Allon, M., 289, 1052 Bouissou, F., 1023 Collins, A.J., 270, 404, 803 Alper, A.B., 585 Boyce, N., 296 Comi, N., 229 Amaral, S., 958 Bozzola, C., 330 Connor, A., 649 Amidone, M., 133 Brady, T., 958 Conte, G., 908 Andreozzi, F., 688 Bragg-Gresham, J.L.; 602 Cook, W.J., 681, 885 Appel, G.B., 641 Branten, A.J., 248 Cooke, C.R., 336 Appel, L, 78, 901 Brunzell, J.D., 69 Coppo, R., 441 Araya, C.E., 119 Budoff, M.J., 412 Coppolino, F., 326 Arend, L., 782 Bunnapradist, S., 890 Coresh, J., 21, 918 Arias, M., 989 Burset, M., 257 Cornish-Zirker, D., 7 Arrigain, S., 703 . Byron, D., 885 Cortese, C., 3:xlv Ars, E., 257 Costacou, T., 721 Asai, O., 47 Calcara, G., 326 Cotant, C.L., 1033 Asano, Y., 602 Cameron, J.D., 622 Cotter, D., 538 Atar, E., 4: Campese, V.M., 197 Craig, J.C., 967 Camsari, T., 143 Curtis, B.M., 733 Bachar, G.N., 4:1i Canavese, C., 330 Cutrupi, S., 1001 Baines, L.S., 834 Cannella, G., 133 Czira, M.E., 813 Bairaktari, E., 463 Carlton, D., 289 Baird, B.C., 791 Carney, J.K., 239 Dallapiccola, B., 688 Baldanza, D., 908 Carter, T.B., 885 Danovitch, G.M., 890 Baldwin, I., 296 Cassottana, P., 133 Dansby, L.M., 885 Ballarin, J., 257 Cavdar, C., 143 Davenport, P., 296 Banerjee, R., 782 Celik, A., 143 Day, C.J., 36 Barbieri, S., 1053 Chan, M., 574 Debelle, F.D., 686 Barenbaum, L.L., 791 de Boer, I.H., 69 Barregard, L., 938 Chang, C.-H., 124 De Cosmo, S., 688 Barrett, B.J., 733 Chang, C.-J., 124 De Deyn, P.P., 279 Basile, A., 2:xliii, 326 Chang, H.-W., 124 Dekker, F.W., 542 Bastani, B., 3:xlv Chang, S.H., 612 Dember, L.M., 696 Battaglia, M.C., 1028 Charansonney, O.L., 559 De Nicola, L., 908 Batwara, R., 826 Chauveau, D., 1023 Deray, G., 203 Baumelou, A., 203 Cheema, B., 574 de Rijke, Y.B., 542 Bax, J.J., 219 Chen, C.-H., 743 Desai, A.G., 631 Bayer, A.S., 342, 343 Chen, C.-S., 754 de Sanctis, C., 441 Bayoumi, A.M., 421 Chen, H., 946 De Smet, R., 279 Beck, G.J., 404 Chen, J., 21, 754 De Terlizzi, F., 441 Becker, B.N., 631 Chen, N., 1037 Detrano, R., 412 Bellanné-Chantelot, C., 1023 Chen, P.-Y., 124 Deysher, A.E., 21 Bellomo, R., 296 Chen, W.-Y., 124 Dharnidharka, V.R., 119 Besarab, A., 989 Cheng, V.C.-C., El Di Paolo, S., 314 Beyea, A., 151, 1053 Cheong, H.I., 765 Diskin, C.J., 344, 885 American Journal of Kidney Diseases, Vol 50, No 6 (December), 2007: pp 1061-1076 1062 Author Index Dixon, B.S., 696 Gillespie, B.W., 602 Ireland, J.H.E., 855 Djamali, A., 631 Gillin, A., 574 Iseki, K., 927 Djurdjev, O., 733 Glodny, B., 1020 Ishikawa, E., 455 Do, J.-Y., 98 Go, A.S., 552 Ito, K., 455 Dong, X., 1037 Gobel, H., 6:xli Ito, S., 927 Doria, A., 688 Goehl, H., 296 Iversen, B.M., 396 Dougherty, F.C., 989 Goldfarb, D.S., 146 Iwano, M., 47 Douglas, J., 78 Goldfarb-Rumyantzev, A.S., 791 Ix, J.H., 412 Dowie, D., 78 Goldstein, M.J., 645 Izzedine, H., 203 Druml, W., 952 Gonzalez, E.A., 59 Duan, X., 754 Gorman, G.H., 958 Jadoul, M., 167 du Buf-Vereijken, P.W., 248 Granata, A., 2:xliii, 326 Jang, H.R., 765 Dumazer, P., 1023 Grasso, M., 146 Jang, M.-H., 98 Dunbar, J., 649 Graves, E., 885 Jassal, S.V., 90 Dunkelgriin, M., 219 Greenberg, A., 904 Jeevanantham, V., 687 Greene, T., 21, 404 ‘Jeon, U.S., 765 Egbuna, O., 468 Grimm, R., 188 Jindal, R.M., 834 Elisaf, M., 463 Groggel, G.C., 450 Johanning, J.M., 450 Elliott, M.J., 433 Gu, D., 754 Johnson, D.W., 967 Ellis, D., 721 Guitard, J., 1023 Johnson, E.S., 559 Eloot, S., 279 Gulay, H., 143 Johnson, R.J., 655 Erhard, P., 305 Guugor, O., 143 Joo, K.W., 765 Erlinger, T., 78 Estrada, E., 289 Haase, M., 296 Kaider, A., 952 Ethier, J., 566, 602 Haase-Fielitz, A., 296 Kakaidi, V., 463 Habib, A.N., 791 Kalil, R., 830 Fadrowski, J.J., 958 Hakim, R.M., 366, 379 Kane, R., 270 Faguer, S., 1023 Halevy, D., 166 Kanna, B., 687 Fan, D., 552 Hamm, L.L., 754 Kao, T.-W., 124 Fealy, N., 296 Han, E., 946 Karabay, O., 343 Fennell, R.S., 119 Han, J.S., 765 Kasiske, B.L., 354 Fenoglio, R., 1053 Harada, K., 47 Katayama, K., 455 Feringa, H.H.H., 219 Harper, L., 36 Katz, D.A., 830 Fernandez-Llama, P., 257 Harris, R., 946 Katz, R., 239, 412 Figuera, M., 2:xliii, 326 Hasselblad, V., 108 Kaufman, J., 538 Fink, J.C., 774 He, J., 754 Kaysen, G.A., 552 Fivush, B., 958 Henderson, J.M., 855 Keijzer-Veen, M.G., 542 Foley, R.N., 270 Heo, N.J., 765 Kellerman, P.S., 673 Fornadi, K., 813 Hernan, M.A., 538 Kellum, J.A., 1 Frankenfield, D., 958 Hewins, P., 36 Kelly, J., 574 Freedman, B.L., 11 Highton, J., 649 Kendrick, C., 78 Fried, L., 239, 721 Himmelfarb, J., 108, 379 Kerr, P.G., 622 Fuiano, G., 229 Hishida, A., 927 Kestenbaum, B., 69, 239 Fuke, H., 455 Hochhalter, A.K., 270 Khan, A., 830 Funk, G.-C., 952 Hoeks, S.E., 219 Kim, B.-S., 98 Furth, S.L., 958 Hohenstein, A., 594 Kim, C.-D., 98 . Holden, R.M., 433 Kim, D.-J., 98 Gabbai, F.B., 908 Hooda, A., 687 Kim, J., 765 Gaido, M., 441 Horio, M., 927 Kim, S., 687 Garbar, C., 167 Hou, S.H., 1028 Kim, Y.-L., 98 Garg, A.X., 712 Hsu, V.D., 774 Kim, Y.-S., 98 Garvin, P., 3:xlv Huang, C.-Y., 743 Kirwan, C., 371 Gassman, J., 78 Huang, K.-H., 743 Kleinveld, H.A., 542 Gemery, J.M., 342, 343 Hughson, M.D., 531 Klinger, M., 989 Gerke, P., 6:xli Hung, N.A., 649 Kneidinger, N., 952 Gerntholtz, T., 989 Hyre, A.D., 585 Koppelstaetter, C., 1020 Gesualdo, L., 314 Korzets, A., 4:1i Gherzi, M., 133 Ikizler, T.A., 379 Kovacs, A.Z., 813 Gianoglio, B., 441 imai, E., 927 Kramer, L., 952 Gilbertson, D.T., 803 Inrig, J.K., 108 Kribben, A., 594 Gillespie, B.S., 108 Ioannou, G.N., 69 Krishnamoorthy, M., 782 Author Index 1063 Krumholz, H.M., 712 Mason, N., 602 Nose, M., 47 Kusek, J., 78, 404 Massart, A., 686 Novak, M., 813 Kutner, N., 585 Mastroroberto, P., 229 Matsell, D., 1:xxxiii O’Brien, K.D., 412 Labriola, L., 167 Matsuo, S., 927 Oh, Y.K., 765 Lacher, D.A., 918 Maw, A.M., 146 Oliver, M.J., 421 Lacson, E. Jr., 379 Maya, I.D., 289, 1052 Onorati, F., 229 Lai, C.-F., 124 McCarthy, E.T., 826 Orchard, T.J., 721 Lai, M.-K., 743 * McDonald, S.P., 612 Ortuno, J., 5:i Lam, R., 90 McGrath, B.P., 622 O’ Sullivan, A., 574 Langmark, F., 396 McNeil, J.J., 622 Ozdemir, D., 343 Lash, J., 78 Megibow, A.J., 146 Paganini, E.P., 703 Laurino, S., 908 Mehta, R.L., | Pan, X., 1037 Lazarus, J.M., 366, 379 Menon, V., 404 Pang, G., 574 Lazzarich, E., 330, 1053 Mewes, R., 594 Panuccio, V., 1001 Lee, H.-J., 98 Meyer, K.B., 691 Paoletti, E., 133 Lee, J.W., 765 Middleton, J., 946 Leehey, D.J., 1028 Midiri, M., 326 Parikh, C.R., 712 Park, S.-H., 98 Legault, L., 566 Miller, W.A., 270 Lehrich, R., 946 * Minutolo, R., 908 Pascual, J., 631 Passler, W., 1020 Leogrande, D., 314 Miskulin, D., 686, 691 Patel, T.S., 11 Lequin, M.H., 542 Mistry, K., 855 Patel, U.D., 108 Leung, N., 155 Moist, L.M., 612 Patti, M.T., 326 Levey, A.S., 5, 21, 169, 349, 404, 918 Molitch, M.E., 166 Patwardhan, A., 574 Levin, A., 1, 733 Molitoris, B.A., | Pavlakis, M., 468 Levy, J.B., 371 Molnar, M.Z., 813 Pederson, S.L., 270 Lewis, J., 78, 946 Monga, G., 330 Peixoto, A.J., 712 Lhotta, K., 1020 Monteleone, P., 880 Pépin, M.-N., 566 Li, M., 90 Moossavi, S., 1052 Pereira, B.J.G., 803 Li, Q., 270 “ Morgera, S., 296 Perticone, F., 688 Light, R.P., 1009 Morini, E., 688 Peschel, R., 1020 Lim, C.S., 765 Mougenot, B., 821 Peterson, G., 78 Lin, S.-L., 124 Mucsi, I., 813 Pezzo, F., 229 Lin, Y.-P., 342 Munda, R., 782 Pham, P.-C.T., 1043 Lindner, A., 813 Muntner, P., 585, 754 Pham, P.-T.T., 1043 Lindner, G., 952 Murata, K., 455 Picken, M.M., 1028 Lindsay, R.M., 108 Murray, A.M., 270 Piera, L., 602 Lipkowitz, M., 78 Muske, C., 622 Pittas, A.G., 865 Lloyd, B., 574 Mussa, A., 441 Pizzini, P., 1001 Lo, 3:€.;. 552 Plaisier, E., 821 Lo, W.K., El Plumb, T.J., 450 Lowrie, E.G., 181 Na, K.Y., 765 Poggio, E.D., 21 Lu, C.-S., 124 Naimark, D.M.J., 421 Poldermans, D., 219 Lu, L., 305 Nair, R., 830 Polkinghorne, K.R., 612 Lubowsky, N.D., 865 Nakatani, K., 47 Pollak, M.R., 855 Lui, S.-L., El Nanovic, L., 673 Porta, F., 441 Lund, B., 450 Narayan, R., 345 Porter, E., 90 Lynch, T.G., 450 Nauta, J., 542 Prendiville,J. , 1:xxxiii Navaneethan, S.D., 687 Presta, P., 229 Macdougall, I.C., 358 Neff, R.T., 345 Probstfield, J.L., 412 MacGinley, R., 649 Neiberger, R.E., 119 Prudente, S., 688 Madero, M., 404 Nelson, R.G., 166 Psychogios, N., 463 Madias, N.E., 184 Neu, A.M., 958 Pu, Y.-S., 743 Magil, A., 1:Xxxili Neumann, P.J., 362 Makino, H., 927 Neumayer, H.-H., 296 Qazi, R.A., 59 Mallamaci, F., 1001 Newman, A.B., 239 Quaglia, M., 1053 Manzi, J., 21,918 Ng, R.C.K., 855 Quinn, R.R., 421 Marescau, B., 279 Nicolosi, M.G., 441 Martin, K.J., 59 Nigwekar, S.U., 687 Radcliff, L., 885 Martins, J., 5:1i Nitta, K., 927 Radhakrishnan, J., 641 Mascia, S., 908 Nomura, S., 455 Rahman, M., 901 1064 Author Index Rajkumar, S.V., 155 Selvin, E., 918 Tozzo, C., 229 Ranieri, E., 314 Senf, W., 594 Trachtenberg, F., 938 Rao, M., 803 Serur, D., 645 Trebbin, W., 880 Rao, P.S., 1033 Sesti, G., 688 Tripepi, G., 1001 Rauseo, A., 688 Shafique, R., 336 Trischitta, V., 688 Reddan, D., 108 Shah, S.V., 1 Trucillo, P., 908 Reddivari, V., 3:xlv Sharma, M., 826 Tsai, T.-J., 124 Remillard, B.D., 342, 343 Sharma, R., 826 Tse, K.-C., El Renzulli, A., 229 Shavelle, D.M., 412 Tsetis, D., 326 Reynolds, K., 754 Shi, H., 1037 Tsimihodimos, V., 463 Riegler, P., 1020 Shiiki, H., 47 Tsukamoto, Y., 927 Tupper, D.E., 270 Ritchie-McLean, S., 371 Shin, S.-K., 98 Ritz, E., 344 Shiraki, K., 455 Tuttle, K.R., 166 Rivera, M., 5:li Shlipak, M.G., 239, 412 Rixe, O., 203 Shyr, Y., 946 Uhlig, K., 5 Rodby, R., 946 Siegel, R., 865 Rodriguez-Iturbe, B., 655 Sifil,A. , 143 Vachharajani, T.J., 1052 Rolla, D., 133 Sigal, S.H., 645 van der Heijden, B.J., 542 Romero, F., 655 Sika, M., 78, 946 van Domburg, R.T., 219 Ronco, C., | Singer, J., 733 van Gestel, Y.R.B.M., 219 Ronco, P., 821 Singh, M.F., 574 Vanholder, R., 279 Rosivall, L., 813 Sinha, R., 1:xxxiii Van Lente, F., 21, 918 Rougier, J.-P., 821 Vargemezis, V., 989 Sinsakul, M., 946 Roy-Chaudhury, P., 782 Vassalotti, J.A., 169 Siscovick, D.S., 239 Ruiz, P., 257 Vemireddy, M., 166 Smavatkul, C., 631 Smith, B., 574 Verdonck, P., 279 Vervloet, M., 248 Sadler, J.H., 535 Smith, D.H., 559 Vikse, B.E., 396 Saglam, F., 143 Spolter, Y.S., 774 von Gersdorff, G., 6:xli Saito, Y., 47 Steffes, M.W., 21 Sajjad, I., 834 Stevens, L.A., 21, 169, 918 Sakan, H., 47 Stillman, I.E., 468 Wald, R., 686 Saldarelli, M., 314 Stivelman, J., 108 Walker, L.D., 774 Salifu, M., 834 Stokes, T.J., 885 Walker, R., 649 Salinas-Madrigal, L., 3:xlv Storr, M., 296 Wall, B.M., 336 Salomon, R.G., 305 Stratta, P., 330, 1053 Walz, G., 6:xli Wan, D.W., 645 Samaha, A., 782 Strippoli, G.F.M., 967 Wang, X., 404 Samaniego, M., 631 Stubanus, M., 6:xli Wang, Y., 782 Samejima, K.-i., 47 Sulowicz, W., 989 Wang, Z., 1037 Sanghvi, S.R., 673 Suneja, M., 830 Wanner, C., 700 Santin, S., 257 Svarstad, E., 396 Warady, B., 958 Sarnak, M.J., 8, 239, 404 Sarwar, S., 336 | Szabo, A., 813 Warnock, D.G., | Szczech, L.A., 108 Wasi, N., 3:xlv Satyan, S., 1009 Szeifert, L., 813 Weidanz, F., 36 Savage, C.O., 36 Szentkiralyi. A., 813 Weiner, D.E., 349 Savin, V.J., 826 Weinhandl, E.D., 803 Scarpelli, D., 688 Weiss, M.F., 305 Sceppa, C.C., 404 Tagay, S., 594 Weiss, N.S., 69 Schena, F.P., 314 Takasu, J., 412 Weiss, S., 641 Scherhag, A., 344 Tazon- Vega, B., 257 Welten, G.M.J.M., 219 Schmid, C.H., 21 Tenorio, M.T., 5:1i Wetzels, J.F., 248 Schned, A., 151, 1053 Terada, M., 47 Wiggins, K.J., 967 Schneeweiss, B., 952 Teruel, J.L., 5:li Wilkinson, A.H., 1043 Schouten, O., 219 Teutonico, A., 314 Winchester, J.F., 108 Schulman, G., 946 Thakar, C.V., 703 Wissing, K.M., 686 Schultheif, U.T., 6:xli Thamer, M., 538 Wolfe, R., 622 Schwarz, C., 952 Thorp, M.L., 559 Worley,’S., 703 Scigliano, R., 908 Torra, R., 257 Wu, K.-D., 124 Sedlacek, M., 342, 343 Torremans, A., 279 Wu, M.-S., 124 Seliger, S.L., 8, 774 Toto, R., 78, 108 Wu, X., 754 Subject Index 1065 Xu, R., 688 Yared, J.-P., 703 Zaun, D., 270 Xu, Y., 1037 Yau, CL... 754 Zeringue, A., 59 Yamagata, K., 927 Yildirim, M., 343 Zhan, M., 774 Yamamoto, N., 455 Yip, T.P.-S., El Zhang, J., 782 Yan, F., 1037 Yoneda, K., 455 Yang, C.-C., 124 Yoshimoto, S., 47 Zhang, Y.-Y., 688 Yang, C.-S., 124 Yosipovitch, G., 11 Zimmerman, D., 433 Yang, C.-Y., 342 . Young, E.W., 602 Zoccali, C., 1001 Yang, X., 559 Yu, H.-J., 743 Zoungas, S., 622 Subject Index Articles appearing on AJKD Electronic Pages are referred to by journal number, a colon, the letter E, and a number. Page references to,Supplement 1 (January 2007) are preceded by S1:. AASK Trial and Cohort Study, baseline characteristics of Albumin participants in, 78-89 effect of age, sex and race on urinary markers of kidney Abdominal aortic aneurysm, temporary postoperative wors- damage inthildren, 938-945 ening of renal function associated with higher long- urinary (See Microalbuminuria) term mortality, 219-228 Alkaline phosphatase, neuropeptide Y and markers of osteo- Access, vascular. See Vascular access blast activity in dialysis patients, 1001-1008 ACE inhibitors. See Angiotensin-converting enzyme inhibi- Allograft tors acute bilateral renal cortical necrosis in, 6:xli-xliii N-Acetyl-B-D-glucosamindase, effect of age, sex and race failure, nephrectomy, remission of aseptic inflammatory on urinary markers of kidney damage in children, ascites after, 645-648 938-945 fungal infection causing acute renal failure, 3:xlv—xlvi Acute kidney injury (AKI) Ambulatory blood pressure monitoring, changing timing of after cardiac surgery, improving survival in, 703-711 antihypertensive therapy to reduce nocturnal blood evaluation using fractional excretion of urea and sodium, pressure in CKD, 908-917 566-573 ANCA-associated glomerulonephritis, D-penicillamine-in- improving outcomes from, 1-4 duced, 821-825 prognostic importance of small changes in serum creati- Anemia nine, 712-720 in CKD, KDOQI Clinical Practice Guidelines on hemo- Acute Kidney Injury Network (AKIN), improving outcomes globin target, 474-529 from acute kidney injury, 1-4 dialysis adequacy and, 774-781 Acute renal failure (ARF) hemoglobin correction, comparison of C.E:R.A. adminis- caused by Candida glabrata allograft infection, 3:xlv—xlvi tration methods on, 989-1000 ciprofloxacin crystal nephropathy, 330-335 progression and outcomes in diabetes based on posttrans- intensive insulin therapy for, 371-378 plantation CKD staging, 631-646 from oral sodium phosphate solution for colonoscopy Angiogenesis inhibitor therapies, kidney toxicity, hyperten- bowel preparation, 151-154 sion and, 203-218 in primary B-cell lymphoma, 885-889 Angiotensin-converting enzyme inhibitors with sepsis, high-cutoff HD membrane for cytokine clear- persistent left ventricular hypertrophy after renal trans- ance, 296-304 plantation and, 133-142 Africa, personal perspectives on dialysis in, 880-884 vs. diuretics for initial therapy of uncomplicated hyperten- African Americans, AASK Trial and Cohort Study baseline sion, 188-196, 197-202 characteristics of participants in, 78-89 Antibiotic resistance, HD catheter-related bacteremia in African American Study of Kidney Disease and Hyperten- children and, 119-123 sion (AASK), baseline characteristics of participants Antibiotics in, 78-89 gentamicin for mycobacterial peritoneal dialysis catheter Age, effect on urinary markers of kidney damage in chil- exit-site infections, 1:E1-E5 dren, 938-945 with heparin, for dialysis catheter-related Staphylococcus AKI. See Acute kidney injury aureus bacteremia, 289-295 AKIN (Acute Kidney Injury Network), improving outcomes for peritoneal dialysis-related peritonitis treatment, 967— from acute kidney injury, 1-4 988 1066 Subject Index Anticoagulation Staphylococcus aureus, treatment with antibiotic lock, for chronic atrial fibrillation in hemodialysis, 345-348 289-295 cost-utility analysis for HD patients with atrial fibrillation, Beer potomania, hyponatremia of, high risk of complica- 421-432 tions form, 673-680 Antihypertensive therapy, changing timing to reduce noctur- Bladder urothelial carcinoma recurrence, CKD as risk factor nal blood pressure in CKD, 908-917 after nephroureterectomy, 743-753 Antimicrobial agents, for peritoneal dialysis-related perito- Bleeding risk, from warfarin anticoagulation for HD pa- nitis treatment, 967-988 tients, 433-440 Antineutrophil cytoplasmic antibody-associated glomerulo- Blood pressure. See also Hypertension nephritis, D-penicillamine-induced, 821-825 changing timing of antihypertensive therapy in CKD for Antiplatelet therapy, aspirin prescription, effect on HD out- nocturnal reduction, 908-917 comes, 602-611 interdialytic weight gain in HD patients and, 108-118 Anti-staphylococcal effects, of high-dose aspirin in HD, nocturnal reduction as therapeutic target in CKD, 342(L) 901-903 Anti-vascular endothelial growth factor receptor, renal ef- Blood urea nitrogen (BUN), kinetic behavior during HD, fects of targeting by angiogenesis inhibitors, 181-183 203-218 Body mass index (BMI) Anuria, in infant kidney transplant recipient, 6:xli-xliii glomerular filtration rate, and low HDL in adults with and Anxiety, posttraumatic stress disorder in HD patients and, without CKD, 552-558 594-601 low birth weight, kidney function and, 531-534 ANZDATA (Australia and New Zealand Dialysis and Trans- mortality in CKD and, 404-411 plant Registry), vascular access trends, 612-621 risk of ESRD in China and, 754-764 Aortic compliance, cardiovascular disease outcomes in Bone alkaline phosphatase isoenzyme, neuropeptide Y and CKD and, 622-630 markers of osteoblast activity in dialysis patients, Aortic surgery, temporary postoperative worsening of renal 1001-1008 function associated with higher long-term mortality, Bone density, quantitative phalangeal ultrasound assessment 219-228 in young renal transplant recipients, 441-449 ARF. See Acute renal failure Bone mineral metabolism, control in HD patients, K.DOQI Arterial stiffness, cardioyascular disease outcomes in CKD Clinical Practice Guidelines for, 686(L) and, 622-630 BUN (blood urea nitrogen), kinetic behavior during HD, Arteriovenous access, dialysis catheter-related Staphylococ- 181-183 cus aureus bacteremia treated with antibiotic lock, 289-295 Calcification of heart valves, kidney function, atherosclero- Arteriovenous fistula failure sis and, 412-420 early, neointimal hyperplasia in, 782-790 Cameroon, personal perspectives on dialysis in, 880-884 obesity and, 450-454 Canada, evaluation and treatment of CKD before and at first Ascites, aseptic inflammatory, remission after nephrectomy nephrologist encounter, 733-742 of failed allograft, 645-648 Cancer Aspirin bladder recurrence, CKD as risk factor after nephroureter- high-dose in HD, direct antistaphylococcal effects of, ectomy, 743-753 342(L) evaluation of potential living kidney donor, 1043-1051 prescription, effect on HD outcomes, 602-611 long-term risk in membranous nephropathy, 396-403 proximal tubular dysfunction induced by, 463-467 lymphoma (See Lymphoma) Astragalus membranaceus, for idiopathic membranous ne- metastatic prostate, fibroblast growth factor 23 and hy- phropathy, 1028-1032 pophosphatemia in, 1033-1036 Atherosclerosis, kidney function, aortic valve and mitral an- Candida infections . nular calcification and, 412-420 of allograft causing acute renal failure, 3:xlv—xlvi Atrial fibrillation crescentic glomerulonephritis crescentic in renal allograft chronic, anticoagulation during HD for, 345-348 recipient, 468-470 in HD patients, cost-utility analysis of systemic antico- Cardiac surgery, improved survival in acute kidney injury agulation for, 421-432 after, 703-711 Atypical mycobacteria, peritoneal dialysis catheter-exite site Cardiopulmonary bypass, renal dysfunction, nonpulsatile infections, 1:E1—E5 perfusion vs. pulsatile perfusion using intra-aortic Australia and New Zealand Dialysis and Transplant Registry balloon pump and, 229-238 (ANZDATA), vascular access trends, 612-621 Cardiovascular disease Autoimmune pancreatitis, IgG4-related, tubulointerstitial morbidity/mortality nephritis and, 455-462 aspirin prescription, effect on HD outcomes, 602-611 AVF failure. See Arteriovenous fistula failure in chronic kidney disease, body mass index and, 404— 411 Bacteremia, catheter-related in peritoneal dialysis, lipid lowering therapy and, 791- in children on hemodialysis, 119-123 802 Subject Index 1067 nocturnal blood pressure reduction as therapeutic target in mortality, body mass index and, 404-411 CKD, 901-903 nocturnal blood pressure reduction as therapeutic target outcomes, carotid intima-medial thickness and indices of in, 901-903 arterial stiffness in CKD, 622-630 posttransplantation staging, progression and outcomes in temporary worsening of renal function after aortic surgery type | diabetic kidney transplant recipients, 631-640 associated with higher long-term mortality, 219-228 predicting RRT and mortality in, 559-565 Cardiovascular system evaluation prevalence and predictors of PTSD in HD patients after of kidney transplantation candidates, 890-898 hurricane Katrina, 585-593 of potential living kidney donor, 1043-1051 progression, uric acid and, 239-247 Carotid intima-medial thickness, association with cardiovas- pruritus in, 11-20 cular disease outcomes in CKD, 622-630 as risk factor for bladder recurrence of urothelial carci- Catheters. See also Bacteremia, catheter-related noma after nephroureterectomy, 743-753 complications, national initiative for early placement of subclinical vascular disease of brain in dialysis patients, fistulas and, 379-395 8-9 early placement of fistulas, national initiative for, testing, National Kidney Foundation position statement 379-395 on, 169-180 vascular access trends in Australia and New Zealand, Chronotherapy, changing timing of antihypertensive therapy 612-621 to reduce nocturnal blood pressure in CKD, 908-917 CD16+ monocytes, and fractalkine in lupus nephritis, Churg-Strauss syndrome with ESRD, continuous immuno- 47-58 a suppression for, 36-46 Celecoxib, effect on proteinuria in diabetic kidney disease, 946-95 | Cigarette smoking, nodular glomerulosclerosis in kidney C.E.R.A., comparison of administration methods on Hb transplant recipient, 830-833 level correction efficacy, 989-1000 Ciprofloxacin, crystal nephropathy, 330-335 -Cerebral magnetic resonance, high prevalence of leukoara- Circadian rhythm, changing timing of antihypertensive iosis in PD patients, 98-107 therapy to reduce nocturnal blood pressure in CKD, Cerebrovascular disease, leukoaraiosis in peritoneal dialysis 908-917 patients, 98-107 CKD. See Chronic kidney disease Chemokines, fractalkine and CD16+ monocytes in lupus Clinical performance measures, relationship between, 774— nephritis, 47-58 ’ 781 Chemotherapy, abolishment of permeability activity in ste- Clinical trials. See Randomized controlled trials roid-resistant minimal change nephrotic syndrome, Cockcroft-Gault equation, impact of creatinine calibration 826-829 on, 21-35 Children. See Pediatric patients Cognitive function, acute variation in HD patients, 270-278 Chinese population Cohort study body mass index and risk of ESRD in, 754-764 predicting RRT and mortality in chronic kidney disease, collagen type III glomerulopathy in two brothers, 1037- 559-565 1042 vsequence of progression of albuminuria and GFR decrease Cholesterol in type I diabetes, 721-732 lipid lowering therapy, association with mortality in PD, COL4AS5 gene linkage analysis, from hair root RNA 791-802 samples for X-linked Alport syndrome, 257-269 low HDL, body mass index and glomerular filtration rate Collagenofibrotic glomerulopathy, in two brothers from Chi- in adults, 552-558 nese family, 1037-1042 Chronic kidney disease (CKD) Collagen type IiI glomerulopathy, in two brothers from Chi- carotid intima-medial thickness, cardiovascular disease nese family, 1037-1042 outcomes and, 622-630 Colonoscopy, acute phosphate nephropathy after sodium changing timing of antihypertensive therapy to reduce phosphate solution bowel preparation, 151-154 nocturnal blood pressure in, 908-917 Comorbidity, evaluation of kidney transplantation candi- comparison of administration methods for methoxy poly- dates, 890-898 ethylene glycol-epoetin beta on Hb level correction Compartmental behavior of water-soluble uremic retention efficacy, 989-1000 with diabetes mellitus solutes, evaluation by direct measurements in plasma and erythrocytes, 279-288 glycemia management in, 865-879 hemoglobin target levels for, 687(L) Computed tomographic urography, diagnosis of medullary ergocalciferol therapy, 25-hydroxyvitamin D and PTH sponge kidney, 146-150 level changes from, 59-68 Computed tomography evaluation and treatment before and at first nephrologist of heart valve calcification in kidney disease, 412-420 encounter, 733-742 of nutcracker syndrome, 2:xliii—xliv HDL, body mass index and glomerular filtration rate in Congestive heart failure, prognostic importance of small adults with, 552-558 changes in serum creatinine in acute kidney injury, intensive insulin therapy for, 371-378 712-720 1068 Subject Index Continuous erythropoietin receptor activator, comparison of neuropeptide Y and markers of osteoblast activity in, administration methods on Hb level correction effi- 1001-1008 cacy, 989-1000 relationship between clinical performance measures, 774— Coronary heart disease. See Cardiovascular disease 781 Cost-utility analysis, of anticoagulation for HD patients with sepsis prevention, statins for, 700-702 atrial fibrillation, 421-432 subclinical vascular brain disease and, 8—9 Creatinine, serum Dialysis adequacy calibration compartmental behavior of water-soluble uremic reten- impact on GFR estimating equations, 21-35 tion solutes, direct evaluation of, 279-288 in National Health and Nutrition Examination Surveys, imperial vs. empirical measures of, 691-695 918-926 relationship with other clinical performance measures, modification of Modification of Diet in Renal Disease 774-781 Study equation for Japanese population, 927-937 Dialysis cycle, acute variation in cognitive function in HD small changes in, prognostic importance for acute kidney patients, 270-278 injury, 712-720 Dialysis disequilibrium, acute variation in cognitive func- Crescentic glomerulonephritis tion in HD patients and, 270-278 D-penicillamine induced ANCA-associated, 821-825 Dialysis facility ownership, epoetin dosing in HD patients in renal allograft as fungal infection complication, 468— author’s perspective on, 538-541 470 dialysis provider’s perspective on, 366-370 Critical illness European physician’s perspective on, 358-361 hypernatremia as independent risk factor for mortality, medico-economic perspective on, 362-365 952-957 overview, 349-353 ‘prognostic importance of serum creatinine changes for US physician perspective on, 354-357 AKI, 712-720 Diarrhea, in infant kidney transplant recipient, 6:xli-xliii Crystal nephropathy, ciprofloxacin-induced, 330-335 Disaster planning, prevalence and predictors of PTSD in HD Cyclooxygenase inhibitors, effect on proteinuria in diabetic patients after hurricane Katrina, 585-593 kidnev disease, 946-951 Disease management, evaluation and treatment of CKD be- Cyclosporine A fore and at first nephrologist encounter, 733-742 for multicentric carpal-tarsal osteolysis with nephropathy, Diuretics 649-654 nocturnal blood pressure reduction as therapeutic target in persistent left ventricular hypertrophy after renal trans- CKD, 901-903 plantation and, 133-142 preference over ACE inhibitors for initial therapy of un- Cystatin C, heart valve calcification in kidney disease and, complicated hypertension, 188-196, 197-202 Donor kidney reuse, 3-year follow-up, 143-145 412-420 Donors, kidney Cytokine clearance, using a high-cutoff point HD membrane dynamics of recipient-donor relationships in living kidney cutoff in sepsis complicated with ARF, 296-304 transplantation, 834-854 living, evaluation of, 1043-1051 Death. See Mortality Dyslipidemia Delirium, acute variation in cognitive function in HD pa- body mass index and glomerular filtration rate in adults tients and, 270-278 with and without CKD, 552-558 Depression, posttraumatic stress disorder in HD patients, intensive insulin therapy in kidney disease and, 371-378 594-601 | lipid lowering therapy, association with mortality in peri- Dermatology, chronic kidney disease-associated pruritus, toneal dialysis, 791-802 11-20 Diabetes mellitus Elderly, quality improvement from interdisciplinary geriat- with CKD ric HD rehabilitation care, 90-97 glycemia management in, 865-879 End-stage renal disease (ESRD) hemoglobin target levels for, 687(L) with ANCA vasculitis, continuous immunosuppression type | for, 36-46 albuminuria and decreased GFR progression in, interdialytic weight gain and blood pressure in HD pa- 721-732 tients, 108-118 progression and outcome of CKD based on posttrans- long-term PD patients, comparison of demographic and plantation staging, 631-640 clinical characteristics, 958-966 Diabetic nephropathy, effect of celecoxib on proteinuria in, muscle wasting, effect of intradialytic resistance training 946-951 on, 574-584 Diagnostic accuracy, of evaluating AKI using fractional ex- predicting RRT and mortality in, 559-565 cretion of urea and sodium, 566-573 pruritus in, 11-20 Dialysis. See also specific dialysis modalities risk, body mass index and, 754-764 in Africa, personal perspectives on, 880-884 sequence of progression of albuminuria and GFR decrease impact of near-death experiences on patients, 124—132 in type I diabetes, 721-732 Subject Index 1069 serum vitamin E levels and oxidative protein modification Genetic testing. See also Mutations in HD, 305-313 by direct sequencing of COL4A5 cDNA from hair root Epoetin RNA samples in X-linked Alport syndrome, 257-269 comparison of administration methods on Hb level correc- Gentamicin, for mycobacterial peritoneal dialysis catheter tion efficacy, 989-1000 exit-site infections, 1:E1-E5 dosing in HD patients, dialysis facility ownership and Gerota’s fascia, fenestration as symptomatic treatment of author’s perspective on, 538-541 floating kidneys, 1020-1022 dialysis provider’s perspective on, 366-370 Gitelman syndrome, SLC/2A3 mutations and sodium-chlo- European perspective on, 358-361 ride cotransporter expression in, 765-773 medico-economic perspective on, 362-365 Glomerular filtration rate (GFR) overview of, 349-353 body mass index and ow HDL in adults with and without US physician perspective on, 354-357 CKD, 552-558 Ergocalciferol, serum 25-hydroxyvitamin D and PTH level estimating equations changes in CKD and, 59-68 impact of creatinine calibration on, 21-35 Erythrocyte measurements, of compartmental behavior of modification of MDRS equation for Japanese popula- water-soluble uremic retention solutes in, 279-288 tion, 927-937 Erythropoietin. See Epoetin NKF position statement on CKD testing and, 169-180 ESRD. See End-stage renal disease sequence of progression in type I diabetes, 721-732 Ethical issues, in evaluation of potential living kidney donor, and size at young adult age after ['UGR and very prema- 1043-1051 a ture birth, 542-551 Ethnicity, kidney function, aortic valve and mitral annular Glomerulonephritis. See also Crescentic glomerulonephritis calcification and, 412-420 ANCA-associated, D-penicillamine-induced, 821-825 European physicians, epoetin dosing in HD patients and, crescentic, in renal allograft as fungal infection complica- 358-361 tion, 468-470 .EVEREST, vasopressin V> receptor antagonist for heart fail- poststreptococcal, with acute rheumatic fever, 1:xxxiii-— ure, 904-907 XXXV Exercise, intradialytic resistance training effect on muscle rituximab for renal diseases associated with, 641-644 wasting in ESRD, 574-584 Glucose management Exit-site infections, mycobacterial in peritoneal dialysis, intensive insulin therapy in kidney disease and, 371-378 1:E1-ES ‘ in patients with diabetes and CKD, 865-879 y-Glutamy] transpeptidase, effect of age, sex and race on Fanconi syndrome, salicylate-induced proximal tubular dys- urinary markers of kidney damage in children, 938- function, 463-467 945 Fibroblast growth factor 23, in metastatic prostate cancer Glycemia management, in patients with diabetes and CKD, and hypophosphatemia, 1033-1036 865-879 Financial issues, evaluation of potential living kidney donor, Graft 1043-1051 early placement of fistulas, national initiative for, Fistula 379-395 early failure, 696-699 vascular access trends in Australia and New Zealand, vascular access trends in Australia and New Zealand, 612-621 612-621 Granulomatous interstitial nephritis, secondary to histoplas- Floating kidneys, fenestration of Gerota’s fascia as symp- mosis, 681-685 tomatic treatment of, 1020-1022 Focal segmental glomerulonephritis, with multicentric car- Hair root complementary DNA, linkage analysis for pal-tarsal osteolysis, cyclosporine for, 649-654 X-linked Alport syndrome, 257~269 Focal segmental glomerulosclerosis, novel mutations in HD. See Hemodialysis NPHP4 in consanguineous family with, 855-864 HDL (high density lipoprotein), body mass index and glo- Focal segmental sclerosis, fenestration of Gerota’s fascia as merular filtration rate in adults with and without symptomatic treatment of floating kidneys, CKD, 552-558 1020-1022 Health maintenance organization, predicting RRT and mor- Fractalkine, and CD16+ monocytes in lupus nephritis, tality in chronic kidney disease, 559-565 47-58 Heart failure Fractional excretion of urea, in evaluating acute kidney in- prognostic importance of small changes in serum creati- jury, 566-573 nine in AKI, 712-720 Functional impairment measure, quality improvement vasopressin V, receptor antagonist for, 904-907 through introduction ot interdisciplinary geriatric HD Heart valves, atherosclerosis, kidney function and, 412-420 rehabilitation care, 90-97 Hematuria, in nutcracker syndrome, 2:xliii—xliv Fungal infections Hemodialysis (HD). See also Vascular access of allograft causing acute renal failure, 3:xlv—xlvi acute variation in cognitive function, 270-278 crescentic glomerulonephritis crescentic in renal allograft catheter-related bacteremia in children, 119-123 recipient, 468-470 catheters (See Catheters) 1070 Subject Index early placement of fistulas, national initiative for, intravenous levocarnitine protective effect in HD patients, 379-395 803-812 effect of weightlifting on muscle wasting in ESRD, 574— length of stay, hypernatremia in critically ill and, 952-957 584 Hurricane Katrina, prevalence and predictors of PTSD in epoetin therapy in dialysis facilities (See Dialysis facility HD patients after, 585-593 ownership, epoetin dosing in HD patients) Hydroxynonenal, serum vitamin E levels in HD and, 30Q5- interdialytic weight gain and blood pressure in, 108-118 S45 intravenous levocarnitine protective effect on subsequent- 25-Hydroxyvitamin D month hospitalization, 803-812 albuminuria in NHANES III and, 69-77 kinetic behavior of urea and other marker molecules dur- serum level changes after ergocalciferol therapy for CKD, ing, 181-183 59-68 leukoaraiosis in, 8-9 Hyperglycemia long-term pediatric patients, comparison of demographic intensive insulin therapy in kidney disease and, 371-378 and clinical characteristics, 958-966 management in patients with diabetes and CKD, 865-879 mortality, N-terminal Pro-B-natiuretic peptide and cardiac Hyperlactatemia, pulsatile vs. nonpulsatile perfusion effects troponin T and, 1009-1019 on renal function during cardiopulmonary bypass, outcome, effects of aspirin prescription on, 602-611 229-238 Hypernatremia, in critically ill as independent risk factor for posttraumatic stress disorder in, 594-601 mortality, 952-957 prevalence and predictors of PTSD after hurricane Kat- Hypertension rina, 585-593 AASK Trial and Cohort Study baseline characteristics of quality improvement through introduction ofi nterdiscipli- participants in, 78-89 nary geriatric HD rehabilitation care, 90-97 angiogenesis inhibitor therapies and, 203-318 serum vitamin E levels and oxidative protein modification interdialytic weight gain in HD patients and, 108-118 in, 305-313 nocturnal blood pressure reduction as therapeutic target in vascular access failure, obesity and, 450-454 CKD, 901-903 warfarin anticoagulation bleeding risk for, 433-440 progression and outcomes in type | diabetes mellitus, Hemoglobin based on posttransplantation CKD staging, 63 1-640 for anemia in CKD, KDOQI Clinical Practice Guidelines salt-dependent, pathophysiological mechanisms of, 655— on, 474-529 672 correction, comparison of C.E.R.A. administration meth- uncomplicated, preference for diuretics as initial therapy ods on, 989-1000 over ACE inhibitors, 188-196 higher targets to reduce left ventricular hypertrophy, Hyponatremia 344(L) from beer potomania, high risk of complications from Hemoglobin target level, for patients with diabetes and rapid correction, 673-680 CKD, 687(L) reversible, related to pericardial tamponade, 336-341 HEMO Study, kinetic behavior of urea and other marker Hypophosphatemia, with fibroblast growth factor 23 eleva- molecules during HD, 181-183 tion in metastatic prostate cancer, 1033-1036 Heparin, with antibiotic for dialysis catheter-related Staphy- lococcus aureus bacteremia, 289-295 ICU (intensive care unit), hypernatremia in critically ill as Hepatocyte nuclear factor-1, heterozygous whole-gene dele- independent risk factor for mortality, 952-957 tion, massively enlarged polycystic kidneys in Idiopathic membranous nephropathy monozygotic twins with, 1023-1027 mycophenolate mofetil in, 248-256 Herbal therapy, for idiopathic membranous nephropathy, treatment with Astragalus membranaceus, 1028-1032 1028-1032 Immunoglobulin G4, autoimmune pancreatitis with tubulo- Hereditary kidney disease. See also specific hereditary kid- interstitial nephritis, 455-462 - ney diseases Immunohistochemistry evaluation of potential living kidney donor, 1043-1051 reduced urinary excretion of thiazide-sensitive sodium- novel mutations in NPHP4 in consanguineous family with chloride cotransporter in Gitelman syndrome, focal segmental glomerulosclerosis, 855-864 765-773 High-cutoff-point membranes, for cytokine clearance in sep- of tubulointerstitia! nephritis with IgG4-related autoim- sis with ARF, 296-304 mune disease, 455-462 High density lipoprotein (HDL), body mass index and glo- Immunology, evaluation of kidney transplantation candi- merular filtration rate in adults with and without dates, 890-898 CKD, 552-558 Immunosuppressive therapy Histoplasmosis, secondary granulomatous interstitial ne- continuous in ESRD of ANCA vasculitis, 36-46 phritis and, 68 1-685 with mycophenolate mofetil for idiopathic membranous Hodgkin disease treatment, abolishment of serum perme- nephropathy, 248-256 - ability activity in steroid-resistant minimal change Infant kidney transplant recipient, diarrhea and anuria in, nephrotic syndrome, 826-829 6:xli-xliii Hospitalization Infections. See also specific types of infections